Investment Thesis
Autolus demonstrates impressive 644.9% YoY revenue growth from product commercialization, indicating market traction. However, the company operates at an unsustainable -273% net margin with -$68M annual free cash flow burn. At this trajectory, the $130.9M cash position provides only 18-24 months of runway, necessitating dilutive equity financing before achieving profitability.
Strengths
- Exceptional 644.9% YoY revenue growth signals successful product commercialization and market adoption
- Strong liquidity position with $130.9M cash, 5.8x current ratio, and zero long-term debt eliminates near-term solvency risk
- Equity-financed capital structure avoids debt service obligations, preserving cash for operations and development
Risks
- Severe unprofitability with -273% net margin and -$59.5M operating loss on only $26.2M revenue is structurally unsustainable
- Negative free cash flow of -$68M annually implies 18-24 month cash runway, requiring dilutive equity financing within 12-24 months
- Biotech sector inherent risks including regulatory setbacks, clinical trial failures, competitive threats, and efficacy/safety concerns
Key Metrics to Watch
- Gross margin when disclosed - critical indicator of whether revenue scale improves unit economics and path to profitability
- Quarterly revenue growth rate - watch for inflection point where revenue growth accelerates relative to cost base
- Cash burn rate and cash position trajectory - determines financing need timing and magnitude of shareholder dilution risk
Financial Metrics
Revenue
26.2M
Net Income
-71.6M
EPS (Diluted)
$-0.27
Free Cash Flow
-68.0M
Total Assets
527.1M
Cash
130.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-227.0%
Net Margin
-273.1%
ROE
-65.8%
ROA
-13.6%
FCF Margin
-259.4%
Balance Sheet & Liquidity
Current Ratio
5.80x
Quick Ratio
5.28x
Debt/Equity
0.00x
Debt/Assets
79.4%
Interest Coverage
-5.35x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:38:23.908609 |
Data as of: 2026-03-31 |
Powered by Claude AI